CASI Pharmaceuticals Files 2024 Annual Report
Ticker: CASIF · Form: 20-F · Filed: Mar 31, 2025 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 20-F |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, 20-F, pharmaceuticals
TL;DR
CASI Pharma dropped its 2024 20-F, check financials for Beijing-based drug maker.
AI Summary
CASI Pharmaceuticals, Inc. filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, formerly known as CASI Pharmaceuticals Holdings, Inc. until January 18, 2023, is based in Beijing, China. The filing details its financial position and business operations within the pharmaceutical preparations industry.
Why It Matters
This filing provides investors with a comprehensive overview of CASI Pharmaceuticals' financial health and strategic direction for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a foreign private issuer filing a 20-F, the company operates under different regulatory and reporting standards than domestic US companies, which can introduce unique risks.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the reporting period for financial statements.)
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer of the 20-F report
- CASI Pharmaceuticals Holdings, Inc. (company) — Former name of the filer
- 20241231 (date) — Fiscal year end date
- 20250331 (date) — Filing date
- 001-41666 (dollar_amount) — SEC File Number
FAQ
What were the primary business activities of CASI Pharmaceuticals in 2024?
The filing indicates CASI Pharmaceuticals operates in the Pharmaceutical Preparations industry (SIC code 2834), but specific activities for 2024 would require a deeper dive into the full report.
When did CASI Pharmaceuticals change its name from CASI Pharmaceuticals Holdings, Inc.?
The company's name change from CASI Pharmaceuticals Holdings, Inc. to CASI Pharmaceuticals, Inc. occurred on January 18, 2023.
Where is CASI Pharmaceuticals headquartered?
CASI Pharmaceuticals, Inc. is headquartered in Beijing, China, with its business address listed at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing.
What is the SEC file number for CASI Pharmaceuticals?
The SEC file number for CASI Pharmaceuticals, Inc. is 001-41666.
What is the SIC code associated with CASI Pharmaceuticals?
The Standard Industrial Classification (SIC) code for CASI Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on March 31, 2025 regarding CASI Pharmaceuticals, Inc. (CASIF).